-
Shenzhen Neoimmune Co., Ltd is set to debut at the Diagmand 2025 Ex-Vivo Diagnostics Innovation Summit.
As an innovative enterprise in the IVD industry,Shenzhen Neoimmune Co., Ltd is committed to the prof...
27
2025.05
-
Shenzhen Neoimmune Co., Ltd successfully obtained ISO 9001:2015 international quality management system certification – empowering industry benchmarks through exceptional quality
On April 11, 2025, Shenzhen Neoimmune Co., Ltd successfully passed the ISO 9001:2015 international q...
15
2025.04
-
ASH 2024 - Shenzhen Neoimmune Co., Ltd's DLBCL MRD Research Findings Selected for the 66th ASH Annual Meeting
The 66th American Society of Hematology (ASH) Annual Meeting will be held from December 7th to 10th,...
05
2024.12
-
Congratulations! Shenzhen Neoimmune Co., Ltd's product has been selected for the 2024 VBEF Healthcare Industry Innovation Product List.
From May 8th to 10th, 2024, the 8th Future Healthcare Ecosystem Expo (VBEF) took place in Beijing. T...
10
2024.05
-
[New Product Launch] - Shenzhen Neoimmune Co., Ltd Detection Product: NEO-SH
On April 11, 2023, Pan-In Medical released a new product: NEO-SHM. This product is based on the inde...
12
2023.04
-
Shenzhen Neoimmune Co., Ltd announced the completion of tens of millions of RMB in PreA financing.
On November 25, 2021, clinical immunology diagnosis and treatment enterprise Shenzhen Neoimmune Co.,...
09
2022.03
-
The first domestic hematological tumor MRD detection product was approved by CE, and Shenzhen Neoimmune Co., Ltd has built a benchmark enterprise for clinical immunodetection
MRD (Minimal Residual Disease) refers to the state of trace tumor cells remaining in the body after ...
09
2022.03
-
Good News! Congratulations to Shenzhen Neoimmune Co., Ltd for successfully achieving the "Specialized, Sophisticated, Specialized, and Innovative" SME recognition in
The significance of developing Specialized, Sophisticated, Specialized, and Innovative SMEs has been...
05
2024.01